Short description
Synchroneuron is a biopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders.
Description
Synchroneuron is a biopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders. Its lead candidate SNC-102, a sustained-release formulation of acamprosate calcium is being evaluated in phase 2 trials for tardive dyskinesia (TD) and Tourette syndrome (TS) and in phase 1 trials for combat-related posttraumatic stress disorder (cPTSD).
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Newton, Massachusetts, United States, North America
Founded on
January 1, 2011
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$1230 - 4560
Sign in for full access
Investors
Nopepepe
Sign in for full access
Founders
Barry S. Fogel, Kei-Lai L. Fong, Marc R. Cote, William D Kerns